AXSM
NASDAQ · Pharmaceuticals
Axsome Therapeutics Inc
$129.80
-7.20 (-5.26%)
Financial Highlights (FY 2026)
Revenue
672.62M
Net Income
-192,964,882
Gross Margin
92.6%
Profit Margin
-28.7%
Rev Growth
+133.7%
D/E Ratio
3.25
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 92.6% | 40.7% | 40.7% | 40.7% |
| Operating Margin | -27.7% | 41.2% | 40.3% | 36.6% |
| Profit Margin | -28.7% | 30.1% | 28.3% | 25.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 672.62M | 1.74B | 1.62B | 1.85B |
| Gross Profit | 622.58M | 706.12M | 659.87M | 751.81M |
| Operating Income | -186,585,659 | 716.08M | 654.27M | 676.39M |
| Net Income | -192,964,882 | 523.27M | 458.37M | 478.59M |
| Gross Margin | 92.6% | 40.7% | 40.7% | 40.7% |
| Operating Margin | -27.7% | 41.2% | 40.3% | 36.6% |
| Profit Margin | -28.7% | 30.1% | 28.3% | 25.9% |
| Rev Growth | +133.7% | -6.3% | -6.3% | +7.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.89B | 4.75B | 4.36B | 4.79B |
| Total Equity | 891.40M | 7.86B | 6.74B | 7.99B |
| D/E Ratio | 3.25 | 0.60 | 0.65 | 0.60 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -179,900,016 | 948.73M | 868.54M | 1.03B |
| Free Cash Flow | — | 423.20M | 592.85M | 532.32M |